136 related articles for article (PubMed ID: 37146833)
21. Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer.
Huang R; Huang D; Dai W; Yang F
Mol Cell Biochem; 2015 Jun; 404(1-2):251-7. PubMed ID: 25772486
[TBL] [Abstract][Full Text] [Related]
22. Overexpressing of POU2F2 accelerates fracture healing via regulating HMGA1/Wnt/β-catenin signaling pathway.
Zhang W; Zhao H; Chen K; Huang Y
Biosci Biotechnol Biochem; 2020 Mar; 84(3):491-499. PubMed ID: 31782345
[TBL] [Abstract][Full Text] [Related]
23. miR-142-3p simultaneously targets HMGA1, HMGA2, HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo metastatic potential of human cervical cancer cells.
Sharma P; Yadav P; Jain RP; Bera AK; Karunagaran D
Life Sci; 2022 Feb; 291():120268. PubMed ID: 34973275
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer.
Ma Y; Marinkova R; Nenkov M; Jin L; Huber O; Sonnemann J; Peca N; Gaßler N; Chen Y
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232331
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice.
Di Cello F; Shin J; Harbom K; Brayton C
Biochem Biophys Res Commun; 2013 Apr; 434(1):70-4. PubMed ID: 23545254
[TBL] [Abstract][Full Text] [Related]
26. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
27. Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer.
Maurizio E; Wiśniewski JR; Ciani Y; Amato A; Arnoldo L; Penzo C; Pegoraro S; Giancotti V; Zambelli A; Piazza S; Manfioletti G; Sgarra R
Mol Cell Proteomics; 2016 Jan; 15(1):109-23. PubMed ID: 26527623
[TBL] [Abstract][Full Text] [Related]
28. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
29. HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche.
Xian L; Georgess D; Huso T; Cope L; Belton A; Chang YT; Kuang W; Gu Q; Zhang X; Senger S; Fasano A; Huso DL; Ewald AJ; Resar LMS
Nat Commun; 2017 Apr; 8():15008. PubMed ID: 28452345
[TBL] [Abstract][Full Text] [Related]
30. HMGA1 accelerates the malignant progression of gastric cancer through stimulating EMT.
Jin GH; Shi Y; Tian Y; Cao TT; Mao Y; Tang TY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3642-3647. PubMed ID: 32329839
[TBL] [Abstract][Full Text] [Related]
31. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
32. HMGA1 Regulates the Expression of Replication-Dependent Histone Genes and Cell-Cycle in Breast Cancer Cells.
Petrosino S; Pacor S; Pegoraro S; Gazziero VA; Canarutto G; Piazza S; Manfioletti G; Sgarra R
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614035
[TBL] [Abstract][Full Text] [Related]
33. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
Front Immunol; 2021; 12():619209. PubMed ID: 33790893
[TBL] [Abstract][Full Text] [Related]
34. High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.
Wang L; Zhang J; Xia M; Liu C; Zu X; Zhong J
Int J Biol Sci; 2022; 18(11):4414-4431. PubMed ID: 35864955
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
[TBL] [Abstract][Full Text] [Related]
36. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
37. LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.
Ma HZ; Wang J; Shi J; Zhang W; Zhou DS
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):5933-5945. PubMed ID: 32572906
[TBL] [Abstract][Full Text] [Related]
38. High mobility group A1 and cancer: potential biomarker and therapeutic target.
Shah SN; Resar LM
Histol Histopathol; 2012 May; 27(5):567-79. PubMed ID: 22419021
[TBL] [Abstract][Full Text] [Related]
39. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
40. High mobility group A1 protein modulates autophagy in cancer cells.
Conte A; Paladino S; Bianco G; Fasano D; Gerlini R; Tornincasa M; Renna M; Fusco A; Tramontano D; Pierantoni GM
Cell Death Differ; 2017 Nov; 24(11):1948-1962. PubMed ID: 28777374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
